G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is currently advancing three clinical-stage oncology programs. Two of our product candidates, trilaciclib and lerociclib, have broad therapeutic potential and may serve as backbone therapies for multiple combination regimens. Our third product candidate, G1T48, is a potential best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of estrogen receptor-positive (ER+) breast cancer. All three investigational therapies have the potential to become new standards of care for women living with breast cancer and provide benefit at early stages of their disease, including in the adjuvant setting. G1 owns or holds an exclusive license for worldwide commercial rights to each of its product candidates. Source
No articles found.
Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on ...
Alder BioPharmaceuticals is a clinical-stage bi...
Fisher Wallace manufactures and markets wearable medical devices for the treatment...
Fisher Wallace manufactures and markets wearabl...
STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, de...
STAAR, which has been dedicated solely to ophth...
Autolus is a clinical-stage, biopharmaceutical company, focused on the development...
Autolus is a clinical-stage, biopharmaceutical ...
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focu...
Strongbridge Biopharma is a global commercial-s...
Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibi...
Summit Therapeutics is a leader in antibiotic i...
Agenus is an immuno-oncology company designed to deliver innovation with speed for...
Agenus is an immuno-oncology company designed t...
Join the National Investor Network and get the latest information with your interests in mind.